Abilify Maintena (Aripiprazole) Patent Expiration, LOE Window & CMS Spending

Abilify Maintena (Aripiprazole) by Otsuka Pharmaceutical: FDA Orange Book LOE 2027-03-02, 14 AB generics, $1.45B 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorOtsuka Pharmaceutical
FDA Application & PathwayN021436 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2027-03-02
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$1.45B
2024 Medicare Part D Spend$644.2M
2024 Medicaid Spend$810.0M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 19.5% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Otsuka Pharmaceutical across sibling Meru public-data platforms.